Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EPAD

- PMLiVE

Who’s calling the shots in European healthcare?

Patients versus Pharma: industry too powerful, and too cosy with EMA, says Yannis Natsis

- PMLiVE

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

Latest BACE inhibitor to run into trouble

- PMLiVE

European elections: Eurosceptics and Greens rise, but big parties hold on

Horse-trading over top jobs now begins

- PMLiVE

Bicycles Therapeutics enters dementia discovery with venture capital fund

Ambitious UK biotech expands research scope

- PMLiVE

Otsuka’s Alzheimer’s agitation drug hits the mark

Drug addresses one of the most challenging symptoms in dementia care

- PMLiVE

Undeterred by aducanumab failure, Eisai and Biogen plough on

Investors sceptical, though mechanism different

- PMLiVE

Where next in Alzheimer’s disease R&D?

How past failures and emerging biology are reshaping drug development

- PMLiVE

Biogen and Eisai pull plug on Alzheimer’s drug

Further undermines amyloid-targeting approach

Brain power: fresh approaches to Alzheimer’s drug discovery

New alliances are learning from past mistakes and breaking down research barriers

- PMLiVE

GW Pharma’s cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK

- PMLiVE

Europe closer to biosimilar rule change, despite fierce resistance from pharma

EFPIA says it weakens IP commitment - supporters say it will boost exports

- PMLiVE

Lilly partners with AC Immune on tau drug for Alzheimer’s

Potential payments of $1.7bn to Swiss firm

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links